BioCryst appoints Charlie Gayer to succeed Jon Stonehouse as CEO

BioCryst Pharmaceuticals has appointed Charlie Gayer as its new CEO, succeeding Jon Stonehouse. Further details regarding this transition are expected to be available in the full article.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin